Hutchison Welcomes Dan O'Korn
Hutchison, a leading provider of strategic business and intellectual property counsel to the life science and technology communities, is pleased to welcome Dan O’Korn to the Firm’s partnership.
Dan O’Korn brings to the firm significant experience in business transactions important to pharmaceutical and biotech companies, including licensing and commercial transactions, FDA-related regulatory matters, asset acquisitions and divestitures, supply agreements, product development agreements and strategic alliances. Dan previously served as outside counsel to life science companies and in in-house counsel roles for Eli Lilly and Company, AAIPharma, Inc., Xanodyne Pharmaceuticals, Inc., and Xcellerex, Inc. Bill Wofford, head of Hutchison’s life science practice, said, “Dan’s impressive background in working with biotech and pharmaceutical companies will strengthen and expand our life science practice. We are delighted that he has joined the Firm.”